Grant: Emerging Team Grant: HIV/AIDS Vaccine Discovery & Social Research - LOI
University of Toronto
$9,450.00
HIV Vaccine Design based on Novel Strategies to induce Protective Mucosal Cellular and Humoral Immunity
FY 2009-10
Summary
Since the publicity of the failed Merck Step trial, there has been a useful change in Vaccine research to consider more subtle but important issues. We rank two factors at the top to achieve success at preventing HIV infection through vaccination: The timing (earliest), and the targeting (mucosal) of the immune response are issues of importance and precision. We propose to capitalize more on the early warning systems (innate immunity) that that triggers the immune system (cellular and antibody) to respond against invading HIV at exactly the time of entry at the mucosa site rather than waiting until the virus expands and gets to the blood. This provides the rationale for this team grant. A successful HIV vaccine must stimulate both the antibody and cellular arms of the immune system, both in the blood (systemically) and at the mucosal level. That is achieved through the use of immune stimulator molecules based on the principles and molecules of innate immunity and its regulatory properties. We plan to test in the SIV monkey model, Cytomegalovirus, a virus similar to herpes virus as an HIV vaccine vector that can provide long term mucosal immune cells that are always ready to strike. The rationale is that it these early strikers can attack right at entry when the virus is most vulnerable unlike other vaccines which provide immune cells that wait in the lymph node until the invading virus gets there and has multiplied. Both antibody and cells are needed to immobilize HIV at the mucosa. We plan a novel approach to the generation of mucosal neutralizing (virus killing) antibody against HIV. Using novel structural and molecular biology techniques we will build and then test a DNA vaccine which we can then vaccinate to produce a combination of the full-size trimerized HIV Envelope with an immune-regulator molecule as a trimer in three projections. We will test if this more stable structure will result in neutralizing antibody.
Department
Program
Emerging Team Grant: HIV/AIDS Vaccine Discovery & Social Research - LOI
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
188585
Name
Macdonald Kelly S
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Emerging Team Grant : HIV/AIDS Vaccine Discovery and Social Research
Projecttitle
HIV Vaccine Design based on Novel Strategies to induce Protective Mucosal Cellular and Humoral Immunity
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$9,450
Cihrequipment2
$0
Programname2
Emerging Team Grant: HIV/AIDS Vaccine Discovery & Social Research - LOI
Keyworddelim
Cytomegalovirus; Hiv Vaccine; Immunoregulation; Innate Immunity; Neutralizing Antibody
Abstract
Since the publicity of the failed Merck Step trial, there has been a useful change in Vaccine research to consider more subtle but important issues. We rank two factors at the top to achieve success at preventing HIV infection through vaccination: The timing (earliest), and the targeting (mucosal) of the immune response are issues of importance and precision. We propose to capitalize more on the early warning systems (innate immunity) that that triggers the immune system (cellular and antibody) to respond against invading HIV at exactly the time of entry at the mucosa site rather than waiting until the virus expands and gets to the blood. This provides the rationale for this team grant. A successful HIV vaccine must stimulate both the antibody and cellular arms of the immune system, both in the blood (systemically) and at the mucosal level. That is achieved through the use of immune stimulator molecules based on the principles and molecules of innate immunity and its regulatory properties. We plan to test in the SIV monkey model, Cytomegalovirus, a virus similar to herpes virus as an HIV vaccine vector that can provide long term mucosal immune cells that are always ready to strike. The rationale is that it these early strikers can attack right at entry when the virus is most vulnerable unlike other vaccines which provide immune cells that wait in the lymph node until the invading virus gets there and has multiplied. Both antibody and cells are needed to immobilize HIV at the mucosa. We plan a novel approach to the generation of mucosal neutralizing (virus killing) antibody against HIV. Using novel structural and molecular biology techniques we will build and then test a DNA vaccine which we can then vaccinate to produce a combination of the full-size trimerized HIV Envelope with an immune-regulator molecule as a trimer in three projections. We will test if this more stable structure will result in neutralizing antibody.
Competitiondate
200907
Approvedterm2
1 yr 0 mth
Pinamesdelim
Macdonald, Kelly S
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $9,450~ $0~